Activated Matrix Metalloproteinase-2-A Potential Marker of Prognosis for Epithelial Ovarian Cancer

By Wu X.   Li H.   Kang L.   Li L.   Wang W.   Shan B.  

Gynecologic Oncology, Vol. 84, Iss. 1, 2002-01 ,pp. : 126-134

Elsevier

Access to resources Recommend Favorite

Serum Matrix-Metalloproteinase-1 is a Bona Fide Prognostic Marker for Colorectal Cancer

By Tahara Kouichirou  

Annals of Surgical Oncology, Vol. 17, Iss. 12, 2010-12 ,pp. : 3362-3369

Springer Publishing Company

Access to resources Recommend Favorite

Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells

By Thant Aye   Nawa Akihiro   Kikkawa Fumitaka   Ichigotani Yasukatu   Zhang Yangying   Sein Thet   Amin A.R.M.   Hamaguchi Michinari  

Clinical and Experimental Metastasis, Vol. 18, Iss. 5, 2000-09 ,pp. : 423-428

Springer Publishing Company

Access to resources Recommend Favorite

EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma

By Davidson Ben   Goldberg Iris   Berner Aasmund   Kristensen Gunnar   Reich Reuven  

Clinical and Experimental Metastasis, Vol. 20, Iss. 2, 2003-03 ,pp. : 161-169

Springer Publishing Company

Access to resources Recommend Favorite

Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival

By Offersen Birgitte V.   Knap Marianne M.   Horsman Michael R.   Verheijen Jan   Hanemaaijer Roeland   Overgaard Jens  

Acta Oncologica, Vol. 49, Iss. 8, 2010-11 ,pp. : 1283-1287

Informa Healthcare

Access to resources Recommend Favorite